Aptadir Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aptadir Therapeutics - overview
Established
2023
Location
Milan, -, Italy
Primary Industry
Biotechnology
About
Founded in 2023 and based in Milan, Italy, Aptadir Therapeutics operates as a biotechnology company that creates RNA-based treatments for illnesses brought on by abnormal DNA methylation. In September 2024, Aptadir Therapeutics raised USD 1. 6 million in pre-seed funding from CDP Venture Capital, Evotec SE, and Angelini Ventures. Aptadir Therapeutics offers a range of software solutions designed to improve operations across various industries.
The company's offerings include a cloud-based platform that manages project management, collaboration, and workflow automation. The platform allows patients to track common pain points such as communication breakdowns, task tracking, and resource allocation. As of 2024, the firm serves various industries such as technology, healthcare, and finance, with a specific focus on markets in North America and Europe. The company plans to use the funding from September 2024 to optimize its lead asset, Aptadir Ce-49.
Current Investors
CDP Venture Capital, Evotec SE, Angelini Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Medical Software
Website
www.aptadir.com
Verticals
HealthTech
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.